Member Info for benbenbenben

Looks quite significant:

"This makes RAS a strong therapeutic target, but despite having been identified as a drug target for over 30 years, only recently have compounds been developed that show promise in pre-clinical trials"

Affimers going where others can't!

Missing from LSE RNS but if you go to London Stock Exchange website is all there

That last week, Al said Public Health England would be supplying the Delta samples.

He doesn’t say where this study took place, but I suspect there is more to this than meets the eye...

Come on Al!

Interesting to note BAMS being listed again, this time with the AffiDx branding attached...

"The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test and AffiDX® BAMS™ SARSCoV-2 Assay in partnership with Adeptrix Inc."

Back on the table perhaps?

Yes it's standard stuff - if in doubt have a look at Eurasia Mining's AGM resolutions and the Q&A: directors retained the option to raise further funds, despite sitting on a cash pile of c.$14 million from the last raise.

It's just about giving the directors some flexibility in the future.

"I would assume that some changes to the pack/artwork and leaflets would be required"

I don't think so - Al was clear from the outset that the test would be for professional use first until the self-test permissions were gained. However, the test has been designed from the off for self-use; if you have a look at the IFU it reflects this - is very straightforward and easily understood.

As to why Abdx seem to be taking a while, IDK - but rumours abound they are busy producing something...

I checked (should of done before posting) and Neil Bell talks about a different candidate they’ve identified through the AVA 6000 development. I’m sure I’ve seen AVA04 mentioned before though, so I wonder what it’s targeting?

Great find Bella - stuff like this is why I still read this board! Thanks for your efforts.

If you look at the drawings, it says they’ve been testing “AVA04-FcRn binding AFFIMER®fusion”.

I haven’t double checked, but I’m sure they discussed AVA04 in the presentation on Monday as a new clinical candidate?

Great find Bella - stuff like this is why I still read this board! Thanks for the efforts.

If you have a look at the attached drawings, it’s looks like they have been working with AVA04 - I haven’t checked, but I’m sure they discussed this in the presentation this week and said they’d developed AVA04 as a new drug??

And it works!

https://www.londonstockexchange.com/news-article/DVRG/microtox-successful-phase-3-field-trials/15030475

The trolls wanted to get to the bottom of the gap at 154 - when we bounced at 160 they took the positions and gave up trying to manipulated it lower. Whenever there’s been a gap on the chart it’s been the same pattern for the last twelve months.

Agreed Infinis - why secure additional capacity if you do not have confidence it will be used?

I guess it boils down to whether you believe one of the worlds best-performing diagnostics will sell in a pandemic which is unlikely to abate for at least the next 12 months. Personally, I have every confidence there will be significant sales - I think these will emerge over the coming (several) weeks.

FWIW - I also think we will still see significant government orders: prioritising a British-made test has been restated as a key objective multiple times, in addition to a clear policy shift towards 'test to release' in lieu of quarantine. A significant LFT infrastructure has been developed and we have seen mounting evidence of this, I would be very surprised if this was then not deployed when warnings abound of a 'grim winter for the NHS'.

Finally, Al made clear we are still engaged with the Porton Down process, which - given the known difficulties we (and Mologic) have had with Futility Testing - suggests to me there remains strong interest on the part of HMG (why not go with an available alternative, like Surescreen, and reject us outright if this weren't the case?).

Ultimately, I am invested here for the technology platforms - which are incredibly powerful. I totted up the market value of antibodies in therapeutics, diagnostics and processes (in one document I read) to be in excess of $750 billion by 2025. For me, that's the prize - and the performance of our LFT has validated the underlying technology.

I expect the next twelve months to be huge.

GLA, DYOR

No, there is no leak, there was an hour long investor presentation in which it was revealed commercialisation will take longer than many anticipated and margins will be tighter. That's it.

Prior to that, Conifer revealed they had sold down at least some of their holding, jolting confidence.

Additionally, the Government extended Innova's EUA and Mologic began legal action against the Government over it's procurement process - further dampening expectations that the Government would bulk purchase our capacity in the immediate future.

Consequently, the market revalued the company for the present stage of commercial roll out. It will revalue it again when orders become known.

I know some people really want there 154 entry, but lets try and avoid imagining doomsday conspiracy's when reality stares us directly in the face...

Thanks Wiggly - I'd missed this before but it strikes me as quite significant.

Conjecture, but I wonder if 'services' includes a lay user study, or an 'alternative validation pathway'?

@wiggly - where did you see Medusa are now a government supplier, could you link to it? Thanks

It's not filled but buying pressure returned at 160 - gaps can also act as support - so if it pulls away from here that might be it; looks like sellers are becoming exhausted

Puggle - you will also observe that as soon as that gap 'fills' at 154, around 95% of the negative posters on this board will disappear. Funny that...

AS stated clearly in the webinar they are still engaged in Porton Down process. Given numerous tests have passed PD, but we have struggled with their (flawed) “futility testing” (like Mologic), the fact we are still engaged with the process suggests to me their is still a high level of interest on behalf of the Government, who’s states objectives remain in procuring a British based test and moving to a “test to release” system on a national level.

Also worth remembering that Avacta haven't spent the last 12 months developing just a Covid LFT, but a 'scaleable lateral flow architecture', designed for use with A/N swabs, into which new Affimers can be easily be inserted.

So in other words, as long as the sample format remains the same, the process of developing new assays for the same sample format is greatly streamlined.

And as they develop new formats (eg: finger-prick blood, etc), in principle the same rules apply: the Affimer changes, but the architecture remains consistent - over time, you can see how that builds up quite a stable of products...

We've been able to market the test since the CE mark was registered in Europe, last week, as for reasons well established there is no commercial LFT market in the UK for as long as HMG keep giving out free tests.

Clearly commercial roll-out is just that, a roll out - and will take some time. We have had our first distribution agreement confirmed today which is just ten days (including weekends) since EU CE was confirmed.

No other test on the market is being limited by Delta Variant confirmation and so I don't see why this should inhibit our sales.

Overall I am disappointed in how long it has taken us to come to market, but confidence we will see a stream of orders over the coming few weeks.